Jörg Schläpfer
Swissmedic | Head of Staff and External Relations

Regulation is ultimately a human endeavor. At Swissmedic, the ability to protect public health — while enabling responsible innovation — depends on the expertise, judgment and integrity of the people behind every assessment. Talent is therefore not simply an organizational asset; it is the foundation of regulatory credibility.

Talent as a cornerstone of trustworthy regulation

Trustworthy regulation begins with deep scientific understanding. Therapeutic products arrive with highly heterogeneous data packages, complex manufacturing realities and nuanced benefit-risk considerations. Evaluating them requires assessors who can interpret evidence across disciplines — drawing on expertise in clinical medicine, toxicology, pharmacology, quality, biostatistics or epidemiology. It also requires the ability to ask the right questions, detect inconsistencies, and recognize when a medicinal product may carry hidden risks.

Yet individual expertise alone is not sufficient. Regulatory assessment is never a solitary task; it is a collective process anchored in internal bridge-building. At Swissmedic, cross-functional cooperation is the norm: quality specialists work side by side with clinical assessors; inspectors exchange insights with vigilance experts; and legal advisors help translate scientific conclusions into enforceable regulatory outcomes. The result is a decision-making process that is evidence-based, comprehensive and transparent.

This collaborative culture strengthens Swissmedic's ability to detect potential issues early — ideally before they develop into public health risks — and ensures that regulatory actions remain proportionate and scientifically grounded. In this way, talent becomes more than expertise; it becomes a stabilizing force that underpins trust.

Where talent matters most at Swissmedic

The importance of talent is most visible where scientific complexity meets regulatory responsibility — across early advice, authorization procedures and post-market oversight. As therapeutic products become more specialized and development pathways more demanding, Swissmedic relies on highly qualified internal and external experts¹ who can assess data critically, anticipate risks, and guide innovators through regulatory expectations.

This expertise is not static. At Swissmedic, the promotion and development of talent is understood as an ongoing, structured process that supports both organizational resilience and individual growth. Scientific excellence and regulatory judgment are strengthened over time through targeted development, experience with complex cases, and exposure to cross-functional perspectives.

Talent development is embedded in continuous professional dialogue, rather than treated as a separate or exclusive exercise. It may involve participation in complex regulatory projects, exposure to international activities, targeted training or mentoring, and closer involvement in cross-departmental initiatives. In this way, the development of expertise remains closely linked to Swissmedic's operational needs and strategic priorities.

By developing and sustaining expertise over time, Swissmedic reinforces high-quality scientific advice — especially for Swiss biotech companies in early development. Talent development thus becomes bridge-building, connecting individual expertise with institutional continuity and linking today's regulatory challenges with tomorrow's scientific realities.

International talent pools between regulators

Regulatory science does not develop in isolation. Globalized supply chains, rapidly evolving technologies, and increasingly complex clinical evidence demand a level of expertise that no single authority — regardless of size or capacity — can cultivate alone. Participation in international talent pools is therefore essential to Swissmedic's work.

Swissmedic's engagement in the Access Consortium² illustrates this approach. Joint assessments with partner agencies in Australia, Canada, Singapore, and the United Kingdom create direct knowledge-sharing loops, allowing assessors to compare scientific interpretations, align expectations and integrate insights from different regulatory cultures. The result is stronger evaluations and more predictable outcomes, particularly for smaller biotech companies seeking early clarity across multiple markets.

A similar dynamic exists in Project Orbis³, a multilateral initiative for oncology medicines coordinated by the U.S. FDA. Through parallel scientific assessments, Swissmedic experts strengthen their understanding of complex oncology data while contributing Swiss perspectives to global deliberations.

Swissmedic's participation in ICH⁴ and IMDRF⁵ further extends this exchange. By contributing to guideline development and working groups, Swissmedic helps shape global regulatory principles while keeping its assessors at the forefront of emerging methodologies.

Beyond collaboration among high-income authorities, Swissmedic also supports regulatory capacity building worldwide through the WHO–Swissmedic Regulatory Training Programme.⁶ These partnerships foster long-term professional relationships and contribute to a more resilient international regulatory ecosystem.

Across all these platforms, the principle is consistent: talent grows through exchange. Shared expertise flows back into Swissmedic's daily work, raising assessment quality and strengthening Switzerland's attractiveness as a location for biotech innovation.

Ensuring regulatory excellence under changing conditions

Sustaining regulatory excellence requires more than expertise alone. It depends on the ability to retain, motivate, and safeguard talent in an environment where scientific advances accelerate, geopolitical tensions affect supply chains, and expectations for rapid access continue to rise. These conditions underscore the importance of tenacity: the collective determination to uphold high standards even under pressure.

Regulatory complexity has increased markedly in recent years. New therapeutic modalities demand sophisticated assessments, while global instability has sharpened the focus on medicine availability, quality vigilance, and timely response. Swissmedic responds through robust processes and a strong culture of collaboration. When challenges arise, experts from different disciplines work together in integrated teams, ensuring decisions remain consistent, proportionate and evidence-based.

Tenacity is also reflected in Swissmedic's approach to sustaining its workforce. Continuous training, participation in international working groups and engagement in regulatory science help ensure that expertise remains current and effective. At the same time, clear priorities, sound governance and established procedures provide stability even under budgetary and operational constraints.

This stability extends to Swissmedic's external role. Developers, healthcare stakeholders, and international partners rely on Swissmedic as a consistent and credible authority. For Swiss biotech companies in particular, predictable regulatory processes and reliable guidance are strategic assets in an uncertain environment.

"Tenacity is the collective determination to uphold high standards even under pressure."

Conclusion: talent and tenacity as foundations for trust

Together, talent and tenacity form the backbone of Swissmedic's contribution to Switzerland's life sciences ecosystem. Expertise ensures that regulatory decisions are scientifically sound; perseverance ensures that this quality is sustained over time, even as conditions evolve.

By investing in people, fostering collaboration across disciplines and borders, and maintaining a clear commitment to scientific rigor and independence, Swissmedic strengthens the trust placed in regulatory decisions — by innovators, partners, and patients alike.

In doing so, Swissmedic builds the trusted pathways that allow innovation to move securely from research to regulation, and from regulation to patients — safely, efficiently, and with enduring public trust.

References

1. Swissmedic Medicines Expert Committees
2. Access Consortium
3. Project Orbis
4. ICH
5. IMDRF
6. WHO–Swissmedic Regulatory Training Programme